Myllia Biotechnology Joins NVIDIA Inception
Myllia Biotechnology today announced it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.
Myllia is focused on functional genomics at scale in advanced cellular models to map the impact of thousands of genetic perturbations at single-cell resolution. It combines CRISPR perturbation with single-cell RNA sequencing, thus leveraging two transformative technologies to uncover novel drug targets. Myllia also owns one of the largest databases of functional genomics data, which will be instrumental in powering AI models to further our understanding of human cells.
Myllia plans to use the resources available through NVIDIA Inception, including access to technical training, preferred pricing on NVIDIA hardware and software, free cloud credits, and technological assistance, to empower the creation of a foundational model of the human cell. The program will also offer Myllia the opportunity to collaborate with industry-leading experts and other AI-driven organizations.
Thomas Moser, CEO of Myllia Biotechnology, expressed his enthusiasm, saying, “Being part of NVIDIA Inception is a privilege, and we eagerly anticipate the chance to collaborate with fellow AI and life science startups within the network.”
Tilmann Burckstummer, the company’s Chief Scientific Officer, added, “With Myllia's advanced AI-driven tools and models, we’re thrilled about the prospects of further development and enhancement in collaboration with NVIDIA.”
NVIDIA Inception helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.